Menu

Karolinska Lets Macchiarini Go

The embattled artificial organ researcher has been dismissed over the fallout from several misconduct allegations leveled against him.

Mar 24, 2016
Bob Grant

An artificial trachea, similar to those transplanted by Macchiarini, made by seeding an inorganic scaffold with stem cellsUCLThe Karolinska Institute (KI) in Stockholm, Sweden, has parted ways with thoracic surgeon Paolo Macchiarini, stating that he “engaged in conduct and research that is incompatible with a position of employment at KI.”

Macchiarini was once billed as a pioneer in artificial organ transplantation, seeding inorganic trachea scaffolds with patients’ own stem cells and then introducing the resulting organ into patients with compromised respiratory systems. But allegations of misconduct dogged his work, patients he had implanted with artificial tracheae died, and several investigations found varying degrees of truth to claims of malfeasance. In the end, though, the hubbub surrounding Macchiarini was too much for the institute. “It’s impossible for KI to have any kind of collaboration with Paolo Macchiarini any longer,” Mats Engelbrektson, of the KI human resources department, said in a statement announcing the departure. “He has acted in a way that has had very tragic consequences for the people affected and their families. His conduct has seriously damaged confidence in KI and for research in general.”

(Hat tip: Retraction Watch)

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.